Claim ledger

Evidence · idea-017

Home NIV (non-invasive ventilation) with tcCO2 (transcutaneous carbon dioxide)-Guided Titration

8/9
factors scored
4/4
core factors
10/45
claims verified
1
refuted

How to read a tag. Only verified counts toward a score — it means a typed connector resolved this against a primary US federal record. unconfirmed means the Verifier checked and could not confirm, which very often means the source could not be queried at all rather than that the claim is doubtful. refuted means a primary source contradicts it. unverified means nothing has checked it yet.

claim 1verifiedUSAsk ↗
CMS (Centers for Medicare & Medicaid Services) established a national coverage determination titled "Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure (CRF) Consequent to Chronic Obstructive Pulmonary Disease (COPD)", carried in the Medicare National Coverage Determinations Manual Chapter 1, Part 4, Section 240.9, with an effective date of 2025-06-09
jurisdiction: US — confidence: verified — note: all three elements read off the NCD (national coverage determination) Manual itself, not off the coverage-database web page. Title matches verbatim; the manual part is chapter 1 part 4; the section header reads "(Rev. 13808; Issued: 05-29-26; Effective: 06-09-25; Implementation: 10-22-25)", so the…
the full check claimed effective date 2025-06-09 is confirmed. The manual also records "(This NCD last reviewed June 2025.)" — source: ncd 240.9 --expect "Chronic Obstructive Pulmonary Disease" --jurisdiction US → verified, CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4 (Rev. 13808, issued 05-29-26), section=240.9. (The ncd connector initially returned unconfirmed because pypdf was not installed in this environment; the dependency from requirements.txt was installed and the lookup re-run.)
claim 2unconfirmedUSAsk ↗
The national coverage analysis that produced NCD 240.9 (a Medicare national coverage determination number) is identified by CMS as CAG-00465N
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason, not a negative finding. No connector in this repo reads the CMS national coverage analysis / decision-memo database (ncacal-decision-memo), and the NCD Manual section — which is the only CMS primary source reachable here — does not…
the full check carry the tracking number. Its absence from the manual is not evidence the tracking number is wrong; NCD Manual sections do not generally cite their NCA tracking sheet. Needs a human retrieval of the decision memo — source: ncd 240.9 --expect "CAG-00465N" --jurisdiction US → unconfirmed: section exists and was read in full, text does not contain 'CAG-00465N'. CMS Pub. 100-3, chapter 1 part 4, section=240.9.
claim 3verifiedUSAsk ↗
CMS implemented NCD 240.9 through a Change Request transmittal published at cms.gov/files/document/r13808ncd.pdf (transmittal number read from that filename as R13808NCD)
jurisdiction: US — confidence: verified — note: verified on the transmittal number and the implementation date, from the manual's own revision header rather than from the filename: the section 240.9 header reads "(Rev. 13808; Issued: 05-29-26; Effective: 06-09-25; Implementation: 10-22-25)", and the connector's…
the full check source_ref independently records the part as Rev. 13808. So Rev./Transmittal 13808 is the instrument that carried this section into the manual, and the implementation date the Generator left open is 2025-10-22. Not verified: the PDF at that URL was not fetched (no connector reads CMS transmittal PDFs) and the associated Change Request number is still unknown — source: ncd 240.9 --jurisdiction US → verified, CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4 (Rev. 13808, issued 05-29-26), section=240.9.
claim 4unconfirmedUSAsk ↗
NCD 240.9 sets national coverage criteria for both respiratory assist devices (HCPCS (Healthcare Common Procedure Coding System) E0470 (a HCPCS code for durable medical equipment)/E0471) and home mechanical ventilators for chronic respiratory failure consequent to COPD, replacing, for that population, coverage determinations previously left to the discretion of the Medicare Administrative Contractors
jurisdiction: US — confidence: unconfirmed — note: compound claim, and it splits three ways. Confirmed: the NCD does set national criteria for both device categories — section B.I covers "Respiratory Assist Devices (RADs)" with and without a backup rate feature, and section B.II covers "Home Mechanical…
the full check Ventilators", both for CRF consequent to COPD. Not confirmed: the NCD text names no HCPCS code at all — neither E0470 nor E0471 appears in it, so the code-to-NCD linkage is this repo's own and not CMS's wording in this document (the same mismatch recorded on idea-001 claim 9verified). Contradicted in part: section D of the NCD reads "Medicare Administrative Contractors (MACs) may make reasonable and necessary determinations under section 1862(a)(1)(A) of the Social Security Act for any patient seeking initial coverage or continued coverage for RADs or HMVs used as treatment of chronic respiratory failure consequent to COPD." MAC (Medicare administrative contractor) discretion is expressly preserved, not replaced, so "replacing ... determinations previously left to the discretion of the MACs" overstates what the final NCD does. Left unconfirmed rather than refuted because the national criteria themselves are real; a human should decide whether the word "replacing" survives section D — source: ncd 240.9 --expect "home mechanical ventilator" --jurisdiction US → verified; ncd 240.9 --expect "E0471" --jurisdiction US → unconfirmed (text does not contain it); ncd 240.9 --expect "E0470" --jurisdiction US → unconfirmed (text does not contain it); ncd 240.9 --expect "Medicare Administrative Contractor" --jurisdiction US → verified, but in the section-D sentence quoted above. All: CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4, section=240.9.
claim 5refutedUSAsk ↗
The coverage criteria associated with NCD 240.9 contemplate a respiratory assist device with a back-up rate feature delivering high-intensity noninvasive ventilation, characterised as inspiratory positive airway pressure above 20 cm H2O together with a back-up respiratory rate of at least 14 breaths per minute
jurisdiction: US — confidence: refuted — note: the Verifier question the Generator asked for is settled, and the pressure figure is wrong. The final NCD defines the term in one sentence: "By the end of the initial 6-month period, a RAD with backup rate feature must be utilized as high intensity therapy, defined as…
the full check a minimum IPAP ≥ 15 cm H2O and backup respiratory rate of at least 14 breaths per minute." The back-up-rate half of the claim is verbatim correct. The pressure half is not: the threshold in the final determination is IPAP ≥ 15 cm H2O, and the string "20 cm H2O" does not occur anywhere in the section. Recorded as refuted rather than unconfirmed because this is not a wording variance — the NCD's own definition of the same term states a different number, which is the proposed-versus-final distinction the Generator flagged. Note for the Scorer: the connector's own status on the phrase lookup was unconfirmed (a phrase miss is never refuted by the tool); the refuted tag is recorded against the quoted contradicting sentence, and a human may overrule it from that quote. Note also this loosens rather than tightens the coverage envelope, and that the 20 cm H2O figure most likely came from trial practice, not from CMS: HOT-HMV's median ventilator setting was an IPAP of 24 cm H2O (IQR 22-26) — see claim 15verified — source: ncd 240.9 --expect "20 cm H2O" --jurisdiction US → unconfirmed: "exists and was read, but its text does NOT contain the phrase '20 cm H2O'"; ncd 240.9 --expect "IPAP" --jurisdiction US → verified, returning the IPAP ≥ 15 cm H2O sentence quoted above. Both: CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4, section=240.9.
claim 6unconfirmedUSAsk ↗
The DME MAC (durable medical equipment Medicare administrative contractor) local coverage determination L33800 (a Medicare local coverage determination number), "Respiratory Assist Devices", was revised to align with NCD 240.9, and its companion policy article is A52517
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason, not a source silence. Nothing about an LCD (local coverage determination) was looked up in either direction. The only code-keyed instrument here is coverage, which reads a cached CMS coverage-policy index that is not present in this environment, and even with…
the full check the file it answers "does a policy name this code", never "what does L33800 say" or "was it revised". No connector in this repo reads LCD or policy-article text by ID. Settling this needs a human retrieval of L33800/A52517 (and of the proposed DL33800 and response-to-comments A58822 the Generator also saw) — source: coverage E0471 --jurisdiction US → unconfirmed: "No local cache at data/medicare_coverage_policies.csv — Medicare coverage policy for E0471 cannot be checked until it exists." Re-run 2026-09-29 with the coverage cache present: coverage E0471 --jurisdiction US → refuted, "local cache of CMS Medicare Coverage Database (no policy names this code), code=E0471". That refuted is a linkage artefact and is not carried onto this claim (the idea-001 claim 9verified mismatch again): the same cached file carries a row "A52517, Article, Respiratory Assist Devices - Policy Article, version 50, effective 2025-06-09, related LCD L33800" with a blank codes column, and a row "A58822, Response to Comments: Respiratory Assist Devices - DL33800, related LCD L33800". So the cache does show A52517 as the policy article attached to L33800 (the companion half of the claim), and its effective date equals NCD 240.9's (claim 1verified) — consistent with an alignment revision, but a date coincidence is not a read of what changed. The cache holds no LCD rows at all and no article prose, so "revised to align with NCD 240.9" is still unread; the code-keyed connector cannot look a document up by ID. Tag unchanged: unconfirmed.
claim 7verifiedUSAsk ↗
HCPCS code E0471 carries the descriptor "Respiratory assist device, bi-level pressure capability, with back-up rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)"
jurisdiction: US — confidence: verified — note: re-checked 2026-09-29 once the HCPCS Level II cache existed (CMS October 2026 alpha-numeric HCPCS file). The descriptor matches the claim verbatim, character for character, and the code is active (add date 2004-01-01, action effective 2006-04-01, no termination date).…
the full check This settles that the code exists and what it describes — nothing about whether or what it pays (claim 10unconfirmed) or what coverage policy governs it (claims 4, 6). Earlier record kept as history — previous pass: unconfirmed for a tooling reason. The HCPCS Level II cache is absent in this environment, so the descriptor was not checked against a CMS release in either direction. This is a missing-file gap and is not evidence that the code or descriptor is wrong. Worth noting the code number itself is used, unchallenged, throughout the NCD-aligned DME (durable medical equipment) literature; only the verbatim descriptor is open — source: hcpcs E0471 --expect "Respiratory assist device, bi-level pressure capability, with back-up rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)" --jurisdiction US → verified, local cache of CMS HCPCS Level II file, code=E0471 (2026-09-29). History: hcpcs E0471 --jurisdiction US → unconfirmed: "No local cache at data/hcpcs_level_ii.csv — HCPCS Level II code E0471 cannot be checked until it exists. See data/README.md."
claim 8unconfirmedUSAsk ↗
Medicare pays respiratory assist devices with bi-level capability and a back-up rate as capped rental items of durable medical equipment rather than as items requiring frequent and substantial servicing, a classification made in a rule published in the Federal Register on 2006-01-27 titled "Medicare Program; Payment for Respiratory Assist Devices With Bi-Level Capability and a Backup Rate", Federal Register document number 06-798
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason — nothing was queried. The policy connector rejected the citation before making a request: "'06-798' is not a Federal Register document number. The format is YYYY-NNNNN". Pre-2007 Federal Register documents use the older…
the full check numbering scheme (06-nnn / E6-nnnn) that this connector's validator does not accept, so the 2006 rule cannot be reached from here at all. A second, independent route to the payment-category half of the claim is also closed: the DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) payment cache is absent (see claim 10unconfirmed). No web substitute was used. Needs either a human fetch of the 2006 rule or a connector fix for legacy FR document numbers — source: policy 06-798 --expect-type rule --expect "capped rental" --jurisdiction US → unconfirmed: document-number format rejected, nothing queried. Re-check 2026-09-29: the payment-category half is now answered and the 2006-rule half is still unreachable, so the tag stays unconfirmed. Confirmed: the July 2026 DMEPOS fee schedule carries E0471 as category CR ("capped rental items"), on an RR line only (no NU/UE purchase line) — so Medicare does pay it as capped rental today. Still unread: that the classification was made by a rule published 2006-01-27 under that title and document number. policy 06-798 --expect "capped rental" --jurisdiction US → unconfirmed again, same validator rejection ("'06-798' is not a Federal Register document number ... nothing was queried") — the GovInfo text fix does not reach pre-2007 numbering — source: payment E0471 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0471, modifier=RR, schedule=DMEPOS, release=July 2026, category CR; payment E0471 --modifier NU --jurisdiction US → unconfirmed: "has no 'NU' line. Its lines are: RR."
claim 9verifiedUSAsk ↗
TAM (total addressable market) component 1 (code and annual volume) — HCPCS E0471 carries non-zero national Medicare fee-for-service utilization, and the annual allowed-services count for the code is reported at HCPCS-code level in CMS's "Medicare Durable Medical Equipment, Devices & Supplies by Referring Provider and Service" public use file
jurisdiction: US — confidence: verified — note: re-checked 2026-09-29 once the DMEPOS utilization release was cached. National, supplier-billed: 188,380 rental services across 32,920 beneficiaries, rental line only (no purchase line). Read correctly: a rental service is one rental month, so 188,380 is…
the full check rental-months, and the figure for patients is the 32,920 beneficiaries; anything about devices or patients must use the beneficiary count, never services. Data year: the connector says "year not stated in the file"; the cached release URL (data/provenance.json) is mup_dme_ry26_p05_v10_dy24_geor.csv, i.e. reporting year 2026, data year 2024. One precision on the file name: what was read is CMS's DME PUF aggregated by referring-provider geography and service (the national row), a sibling of the provider-level "by Referring Provider and Service" release the claim names; the code-level count exists in the CMS DME PUF series, but the provider-level file itself was not opened. Floor caveat carried: Medicare FFS (fee-for-service) only — excludes Medicare Advantage (Medicare Advantage), commercial, Medicaid, VA and cash-pay — so this is a floor on US volume, never a market size. Earlier record kept as history — previous pass: unconfirmed because the file is missing, not because the code has no volume — the connector says so in terms: "E0471 is a supplier-billed DMEPOS code, and the cached release (medicare_procedure_volumes.csv) covers physician-billed services — it carries essentially no E-prefixed codes at all. Nothing was looked up in either direction. This is a missing-file gap, not evidence that the code has no volume." The release that would answer it is CMS "Medicare Durable Medical Equipment, Devices & Supplies — by Geography and Service" (data.cms.gov), uncached here; see docs/backlog.md 1.13. The claim's own structure — "the number exists and is retrievable from this named file" — is the right shape and survives intact; only the retrieval is blocked. Carry forward, when it is retrieved, that Medicare FFS excludes Medicare Advantage, commercial, Medicaid, VA and cash-pay, so any figure is a floor on US volume and never a market size — source: procedures E0471 --jurisdiction US → verified, local cache of CMS Medicare DMEPOS utilization file (referring provider geography and service), code=E0471, geography=National — "rental 188,380 services / 32,920 beneficiaries" (2026-09-29). History: procedures E0471 --jurisdiction US → unconfirmed (DMEPOS code absent from the cached physician-billed release).
claim 10unconfirmedUSAsk ↗
TAM component 2 (price per unit) — the Medicare DMEPOS fee schedule publishes a monthly rental allowable for HCPCS E0471, and that allowable multiplied by the capped-rental period is the gross Medicare revenue per enrolled patient
jurisdiction: US — confidence: unconfirmed — note: re-checked 2026-09-29; the tooling gap is closed, and the claim now splits — first half confirmed, second half contradicted by the regulation. (1) Confirmed: the July 2026 DMEPOS fee schedule publishes a monthly rental (RR) allowable for E0471, category CR capped…
the full check rental — non-rural $324.35 (AZ) to $347.40 (CO) across 49 contiguous states/DC, rural $520.32–$579.71. These are Medicare allowed amounts, not payments (beneficiary coinsurance comes out of them), and they vary by state and rural ZIP; no competitive-bidding question was examined. (2) Not supported as worded: "allowable × capped-rental period = gross revenue per enrolled patient". 42 CFR 414.229(b)(2) sets the monthly rental amount at "10 percent of the purchase price ... for each of the first 3 months and 7.5 percent of the purchase price for each of the remaining months" — the monthly amount is not uniform across the rental — and 414.229(f)(1) pays "for no longer than a period of continuous use of 13 months", i.e. 13 months is a ceiling reached only by patients who stay medically eligible and, under NCD 240.9, clear the continued-coverage adherence bar (claim 29unconfirmed). So one RR figure times 13 overstates even the ceiling, and is not a per-enrolled-patient figure. Whether the fee schedule's RR value is the month 1–3 rate is not stated in the connector output and is not asserted here. Left unconfirmed rather than refuted because the load-bearing fact (a published monthly allowable) is real and only the arithmetic rule fails; a human may judge the method half refuted from the quoted regulation. The queue replay's verified answers half (1) only and was not carried across as the tag — source: payment E0471 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0471, modifier=RR, schedule=DMEPOS, release=July 2026; regulation 414.229 --title 42 --expect "7.5 percent of the purchase price for each of the remaining months" --jurisdiction US → verified, eCFR versioner title-42, issue 2026-08-13, section=414.229; regulation 414.229 --title 42 --expect "for no longer than a period of continuous use of 13 months" --jurisdiction US → verified, same section. History — previous pass: unconfirmed for a tooling reason. The payment cache is absent in this environment, so no allowable was retrieved and the rural/non-rural and competitive-bidding question the Generator asked about could not be examined either. Missing-file gap, not a finding that no allowable exists — earlier lookup (history): payment E0471 --jurisdiction US → unconfirmed: "No local cache at data/hcpcs_payment_rates.csv — payment rate for E0471 cannot be checked until it exists."
claim 11unconfirmedUSAsk ↗
TAM component 3 (addressable share) — Generator assumption, unsourced: the share of US adults with diagnosed COPD who have chronic hypercapnic respiratory failure meeting NCD 240.9's coverage criteria is a low single-digit percentage of the diagnosed COPD population, and the near-term addressable group is narrower still — patients identified in the weeks after a hospitalised exacerbation, which is the population HOT-HMV enrolled
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent a human-attached licensed or primary source; the market connector is unverifiable by design and no agent pass can close this. One partial anchor is now on the record from a primary source, and it is worth keeping: HOT-HMV screened…
the full check 2,021 patients to enrol 124 eligible (claim 15verified, PubMed PMID (PubMed identifier) 28528348) — a 6.1% screen-to-eligible ratio in a trial population already selected for post-exacerbation hypercapnia. That is a trial-recruitment figure, not a prevalence estimate, and must not be used as one — source: market "share of US adults with diagnosed COPD who have chronic hypercapnic respiratory failure meeting NCD 240.9 coverage criteria is a low single-digit percentage" → unverifiable: "no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."
claim 12unconfirmedUSAsk ↗
TAM component 4 (population base) — approximately 16 million US adults have a diagnosed chronic obstructive pulmonary disease
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed here. No connector in this repo reaches CDC/BRFSS prevalence data (the structural gap already recorded on idea-014), and market is unverifiable by design. Needs a human-attached primary table; the figure is neither confirmed nor challenged…
the full check by anything run this pass — source: market "approximately 16 million US adults have diagnosed chronic obstructive pulmonary disease" → unverifiable: "no free, authoritative, machine-queryable source."
claim 13unconfirmedUSAsk ↗
CPT (Current Procedural Terminology) 95811 is an existing Category I code covering polysomnography for age 6 years or older with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed by design — the claim is about the descriptor text, and CPT descriptors are AMA-licensed and cannot be reproduced or scraped (phase2-spec.md Section 3). Either a human attaches a licensed AMA/vendor source or the claim is rescoped. What…
the full check is now on the record from a free CMS file is that the code number is live and payable on the 2026 PFS (physician fee schedule) — see claim 14unconfirmed, where rvu 95811 returned verified — which settles the "existing Category I code" half without touching the descriptor — source: cpt 95811 → unverifiable: "CPT descriptors are AMA-licensed and cannot be scraped or reproduced verbatim ... no agent pass can close it."
claim 14unconfirmedUSAsk ↗
The payment setting difference this candidate depends on has three sides, none of whose amounts the Generator retrieved: (a) home delivery is paid as a monthly capped-rental DME allowable under E0471 with no facility fee; (b) the attended titration study it is intended to displace (CPT 95811) is performed in a sleep laboratory or hospital and is paid with a facility component; (c) the exacerbation readmissions the therapy is intended to postpone are paid under the inpatient prospective payment system
jurisdiction: US — confidence: unconfirmed — note: re-checked 2026-09-29 from the queue; side (a) now has a number, side (c) is still blocked, and the replay's verified on payment E0471 answers only (a), so the compound tag stays unconfirmed. (a) now answered in part: E0471 is on the July 2026 DMEPOS fee…
the full check schedule as category CR (capped rental), RR line only, non-rural $324.35–$347.40 and rural $520.32–$579.71 per rental month across the contiguous states — Medicare allowed amounts, not payments. That confirms "monthly capped-rental DME allowable under E0471"; "no facility fee" is the absence of a facility component on a DMEPOS supplier claim and was not separately looked up. (b) unchanged: re-run rvu 95811 returns the same 2026 figures. A relevant pointer found this pass, not a tag: the 2020 ATS clinical practice guideline (PubMed PMID 32795139, abstract) states "we suggest not using an in-laboratory overnight polysomnogram to titrate NIV in patients with chronic stable hypercapnic COPD who are initiating NIV" — together with NCD 240.9 not requiring an attended titration (claim 30unconfirmed), this weakens the premise that a 95811 study is routinely the thing displaced. (c) still blocked: drg 190 → unconfirmed, MS-DRG cache absent. Previous pass, kept as history: one of the three sides now has a number and the other two are blocked on missing files. (b) partly answered: rvu 95811 → verified, local cache of the CMS PFS RVU (relative value unit) file, 2026, status A, CF 33.5675 — global (no modifier) work 2.54 + PE 18.37 + MP 0.28 → $711.30; technical component (modifier TC) $586.76, of which the PE portion is $581.05; professional component (modifier 26) $124.54. So roughly 82% of the payment for an attended titration study is the technical component, which is the facility-side money the claim is about. National unadjusted, no GPCI; and the connector's own caveat applies — this says what the PFS pays, never that a facility is separately paid (that is apc/drg). (a) blocked: no DMEPOS allowable, cache absent (claim 10unconfirmed). (c) blocked and the codes still unidentified: the MS-DRG cache is absent, so MS-DRGs 190/191/192 were neither confirmed nor refuted and must continue to be treated as unidentified — source: rvu 95811 --jurisdiction US → verified, local cache of CMS PFS RVU file, code=95811, year=2026; drg 190 --jurisdiction US → unconfirmed: "No local cache at data/ms_drg_weights.csv"; payment E0471 --jurisdiction US → unconfirmed: no local cache [previous pass]. Today (2026-09-29): payment E0471 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0471, modifier=RR, schedule=DMEPOS, release=July 2026; rvu 95811 --jurisdiction US → verified, local cache of CMS PFS RVU file, code=95811, year=2026; drg 190 --jurisdiction US → unconfirmed: "No local cache at data/ms_drg_weights.csv"; literature-detail 32795139 → found, PubMed PMID=32795139 (efetch) — a ScanResult, pointer only.
claim 15verifiedUSAsk ↗
In the HOT-HMV randomised clinical trial (Murphy PB et al., JAMA, 2017-06-06, volume 317, issue 21, pages 2177-2186), adding home noninvasive ventilation to home oxygen therapy in patients with persistent hypercapnia after a life-threatening COPD exacerbation extended median admission-free survival to 4.3 months versus 1.4 months for home oxygen alone, while 12-month mortality did not differ significantly (28.1% versus 32.2%)
jurisdiction: US — confidence: verified — note: every number checks out against the PubMed record of the paper. "The median time to readmission or death was 4.3 months (IQR, 1.3-13.8 months) in the home oxygen plus home NIV group vs 1.4 months (IQR, 0.5-3.9 months) in the home oxygen alone group, adjusted hazard ratio…
the full check of 0.49 (95% CI, 0.31-0.77; P = .002)." On mortality: "At 12 months, 16 patients had died in the home oxygen plus home NIV group vs 19 in the home oxygen alone group" — against 57 and 59 randomised, that is 28.1% and 32.2% exactly as claimed, and the abstract reports no significant difference. The PMID the Generator could not confirm is confirmed: 28528348, JAMA 2017, type "Randomized Controlled Trial", registered NCT00990132 (a ClinicalTrials.gov registration number). Two riders. The record returns year only, so the 2017-06-06 date and the volume/issue/page citation are still unchecked. And the trial is UK-conducted ("recruited from 13 UK centres between 2010 and 2015") — the jurisdiction: US tag on this line is wrong in substance; this is clinical evidence about a mechanism, carrying no US regulatory or reimbursement weight, exactly as the Generator warned. Two figures worth carrying into other claims: 2,021 screened for 124 eligible (claim 11unconfirmed), and median settings of IPAP 24 cm H2O (IQR 22-26), EPAP 4, backup rate 14 (claim 5refuted) — source: literature-detail 28528348 → found, PubMed PMID=28528348 (efetch), https://pubmed.ncbi.nlm.nih.gov/28528348/. Instrument caveat: literature-detail returns a ScanResult, which carries no confidence tag of its own and is not replayable by recheck_claims.py; the verified tag here is recorded against the quoted structured abstract retrieved from PubMed, which is the primary record for the published paper.
claim 16unconfirmedUSAsk ↗
In that same trial, noninvasive ventilation was titrated to overnight measures of transcutaneous CO2 in order to control nocturnal hypoventilation
jurisdiction: US — confidence: unconfirmed — note: the single load-bearing mechanism claim is still not anchored, and this is a real source silence, not a tooling gap. The full PubMed structured abstract for PMID 28528348 was retrieved and read; it describes the design, the population, the interventions and the…
the full check median ventilator settings (IPAP 24, EPAP 4, backup rate 14) but says nothing about transcutaneous CO2 or about what the titration target was. The connector flags the limit itself: "structured abstract — deeper than a title, still not appraised: no methods". The titration protocol lives in the paper's methods section, which no connector in this repo can reach (JAMA full text is paywalled). What is not the case is that the trial is silent on CO2 — enrolment required Paco2 > 53 mm Hg and outcomes were framed around hypercapnia; it is specifically the transcutaneous, overnight, titration-target assertion that is unsupported. This should be the first item a human closes: it is the premise of the whole device — source: literature-detail 28528348 → found, PubMed PMID=28528348 (efetch); abstract contains no mention of transcutaneous CO2 or of a titration target.
claim 17verifiedUSAsk ↗
FDA (US Food and Drug Administration) has published a document titled "Cutaneous Carbon Dioxide (PcCO2) and Oxygen (PcO2) Monitors - Class II (FDA device class II) Special Controls Guidance Document for Industry and FDA", indicating that transcutaneous CO2 monitors are regulated as Class II devices subject to special controls
jurisdiction: US — confidence: verified — note: verified from the regulation text itself, which is a stronger source than the guidance page the Generator saw and closes the gap the Generator left open. 21 CFR (Title 21 of the Code of Federal Regulations) 868.2480 reads: "§ 868.2480 Cutaneous carbon dioxide (PcCO2) monitor. (a) Identification. A cutaneous carbon…
the full check dioxide (PcCO2) monitor is a noninvasive heated sensor and a pH-sensitive glass electrode placed on a patient's skin, which is intended to monitor relative changes in a hemodynamically stable patient's cutaneous carbon dioxide tension as an adjunct to arterial carbon dioxide tension measurement. (b) Classification. Class II (special controls). The special control for this device is FDA's 'Class II Special Controls Guidance Document: Cutaneous Carbon Dioxide (PcCO2) and Oxygen (PcO2) Monitors; Guidance for Industry and FDA.'" The CFR names the guidance by title (word order differs from the claim's rendering; it is the same document) and states the Class II / special-controls status directly. The two fields the Generator did not identify are now identified: CFR section 21 CFR 868.2480, product code LKD, "Monitor, Carbon-Dioxide, Cutaneous", device class 2, review panel AN. Two riders: the guidance document's own text was not opened (no connector reaches FDA guidance, and fda.gov gates automated fetches), so what it requires is unread; and note the CFR's identification frames the device as an adjunct to arterial measurement in a hemodynamically stable patient, which is narrower than this candidate's intended use of overnight home recording as a titration input — that gap is a pre-submission question, not a database fact — source: regulation 868.2480 --title 21 --expect "special controls" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-16, section=868.2480; classification --device-name "monitor, carbon dioxide" --jurisdiction US → verified, openFDA device/classification product_code=LKD.
claim 18verifiedUSAsk ↗
21 CFR 868.5895 is the classification regulation for continuous ventilators, and the Philips Respironics BiPAP AVAPS Ventilatory Support System has been described as classified under that regulation with product code MNS, "ventilator, continuous, non-life-supporting"
jurisdiction: US — confidence: verified — note: all three legs confirmed against primary records, and the K-number the Generator could not capture is K102465 (an FDA 510(k) clearance number). (1) eCFR: "§ 868.5895 Continuous ventilator. (a) Identification. A continuous ventilator (respirator) is a device intended to mechanically control or assist…
the full check patient breathing by delivering a predetermined percentage of oxygen in the breathing gas ... (b) Classification. Class II (performance standards)." (2) openFDA classification for product code MNS: "Device class 2: Ventilator, Continuous, Non-Life-Supporting (regulation 868.5895, review panel AN)" — the exact pairing the claim asserts. (3) The device: 510(k) (premarket notification) K102465, "BIPAP AVAPS VENTILATORY SUPPORT SYSTEM", Respironics, Inc., decided 2011-03-24, and the openFDA record for that clearance carries product_code=MNS. Checked against this file's stated intended_use: — prescription home bi-level NIV with a back-up rate for adults with CRF consequent to COPD, no life support, no automatic setting changes; a change of indication toward life-supporting use or closed-loop control would move this off MNS and invalidate the finding. Not established by this lookup: that this candidate device falls inside MNS. Its Indications for Use, retrieved from the K102465 summary, cover "non-invasive ventilatory support to treat adult and pediatric (> 7 years of age; > 40 lbs) patients with obstructive Sleep Apnea (OSA (obstructive sleep apnoea)) and Respiratory Insufficiency ... in the hospital or home" — it names neither CRF consequent to COPD nor any CO2-recording or titration-recommendation function, so the combined-function half of this candidate has no predicate indication here — source: regulation 868.5895 --title 21 --expect "continuous ventilator" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-16, section=868.5895; classification --product-code MNS --jurisdiction US → verified, openFDA device/classification product_code=MNS; 510k "AVAPS" --applicant "Respironics" --jurisdiction US → verified, openFDA device/510k k_number=K102465; clearance-summary K102465 --jurisdiction US → verified, FDA 510(k) summary K102465 (https://www.accessdata.fda.gov/cdrh_docs/pdf10/K102465.pdf).
claim 19unconfirmedUSAsk ↗
No FDA-cleared device marketed in the US combines a home respiratory assist device with back-up rate and an integrated transcutaneous CO2 recording channel driving practitioner-approved titration recommendations
jurisdiction: US — confidence: unconfirmed — note: re-run keyed on product code as the Generator asked, and it still cannot be verified — an absence-of-evidence claim cannot be closed by a database that returns nulls for devices that exist. What the product-code-keyed scans show: MNS (continuous ventilator,…
the full check non-life-supporting) returns 43 clearances over 2000-01-01 to 2026-09-18, none of whose device names mentions CO2, carbon dioxide or transcutaneous; LKD (cutaneous carbon-dioxide monitor, the code identified this pass — see claim 17verified) returns 9 clearances over the same window, every one a standalone monitor (Sentec SDMS ×4 including K232516 tCOM+ 2024, Radiometer TCM40 and TOSCA, Linde TOSCA 500, Philips IntelliVue TCG10, Perimed PeriFlux 6000) and none a respiratory assist device. So the two halves are cleared under two disjoint product codes with no overlap in the record. That is consistent with the claim and is still not evidence for it, and it must not be scored as white space: a combined device could be cleared under either code without a name that a scan would catch, and clearances is a Stage 0 scan that issues no confidence tag at all — source: clearances --product-code MNS --since 2000-01-01 --until 2026-09-18 --limit 100 --jurisdiction US → found, 43 records, openFDA device/510k; clearances --product-code LKD --since 2000-01-01 --until 2026-09-18 --limit 50 --jurisdiction US → found, 9 records, openFDA device/510k.
claim 20verifiedUSAsk ↗
Federal Register document 2026-16368 (91 FR 51710) states, among the eligibility criteria for the RAPID coverage pathway, "Separately payable devices that can, if approved, be billed to Medicare"
jurisdiction: US — confidence: verified — note: the phrase is in the document verbatim, in the eligibility list, in context: "Not already the subject of a controlling Medicare NCD; Separately payable devices that can, if approved, be billed to Medicare; and Not otherwise excluded from coverage through law or…
the full check regulation." Two things the lookup settles that cut against reading much into this. First, the instrument is a Notice, published 2026-08-11, with a comment period closing 2026-10-13 and no effective date recorded — it states what CMS intends, not a settled requirement, and a published intention is not a policy operating. Second, and more directly: the first criterion in that same sentence is "Not already the subject of a controlling Medicare NCD" — and this candidate's whole reimbursement premise is that NCD 240.9 controls its population (claims 1 and 4). On the document's own words the candidate appears excluded by the criterion immediately preceding the one the Generator cited, which strengthens rather than weakens the Generator's conclusion that no RAPID tailwind should be credited here. Whether that reading is right is interpretation, which this connector does not settle — source: policy 2026-16368 --expect "Separately payable devices that can, if approved, be billed to Medicare" --jurisdiction US → verified, Federal Register document_number=2026-16368 (91 FR 51710), "Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway" (Notice, published 2026-08-11, HHS / CMS).
claim 21verifiedUSAsk ↗
Federal Register document 2026-16368 (91 FR 51710) limits the RAPID coverage pathway to Class II and Class III (FDA device class III) FDA Breakthrough-designated devices
jurisdiction: US — confidence: verified — note: confirmed in the document's own words: "RAPID coverage pathway will provide accelerated Medicare beneficiary access to certain eligible Class II and Class III U.S. Food and Drug Administration (FDA) Breakthrough-designated Devices." Same instrument caveat as claim 20verified — a…
the full check Notice with a comment period closing 2026-10-13, so this is a stated intention, not law, and it may change before anything is finalised. The Generator's planning posture (no Breakthrough assumption, no coverage-timing tailwind credited to this file) is supported by the text and is the conservative read — source: policy 2026-16368 --expect "Breakthrough" --jurisdiction US → verified, Federal Register document_number=2026-16368 (91 FR 51710), Notice, published 2026-08-11, HHS / CMS.
claim 22verifiedUSAsk ↗
Philips issued a voluntary recall notification on 2021-06-14 covering certain ventilators, CPAP devices and bi-level positive airway pressure devices, on the basis of health risks associated with polyester-based polyurethane sound-abatement foam, affecting on the order of 15 million devices worldwide
jurisdiction: US — confidence: verified — note: the recall event, its exact date, the device categories and the stated basis are all confirmed against openFDA device-recall records. Six records carry event date 2021-06-14, all with the same reason text — "The polyester-based polyurethane (PE-PUR) foam may degrade into…
the full check particles which may enter the device's air pathway and be ingested..." — and between them they span exactly the three categories the claim names: Z-1956-2021 (Trilogy 100/200, Garbin Plus, Aeris — ventilators), Z-1957-2021 and Z-1958-2021 (A-Series BiPAP Hybrid A30, BiPAP A40, BiPAP A30 — bi-level), Z-1972-2021 (E30), Z-1973-2021 (DreamStation ASV, DreamStation ST, AVAPS) and Z-1974-2021 (SystemOne Q-Series, DreamStation — CPAP). All six are still "Open, Classified" as of this pass. Two exclusions from the tag. The "on the order of 15 million devices worldwide" figure appears in no openFDA record — it is a company/press number and stays unconfirmed. And the instrument, recalls, is a Stage 0 scan whose ScanResult carries no confidence tag and is not replayable by recheck_claims.py; the tag is recorded against the six quoted primary records, each with its own product-resolution source_ref. Note for competitive-intensity scoring: the same firm-and-year scan returns 12 further 2021 recalls (Trilogy Evo software, 2021-07-26 and 2021-12-22; BiPAP V30 Auto / A40 / A30 motor assemblies, 2021-04-06, since terminated) — source: recalls --firm "Philips Respironics" --since 2021-01-01 --until 2021-12-31 --limit 20 --jurisdiction US → found, 18 records, openFDA device/recall, including product_res_number=Z-1956-2021, Z-1957-2021, Z-1958-2021, Z-1972-2021, Z-1973-2021, Z-1974-2021, all dated 2021-06-14.
claim 23unconfirmedUSAsk ↗
On 2024-04-09 a federal district court entered a consent decree between the United States (Department of Justice on behalf of FDA) and Philips Respironics which, until specified requirements are met, restricts the sale of new CPAP and bi-level sleep-therapy devices and certain other respiratory care devices in the United States from named Philips Respironics facilities
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason — no connector in this repo reaches a court docket, a DOJ filing or an FDA enforcement action. policy reads the Federal Register only, which does not carry consent decrees; recalls and maude are device-event scans and say…
the full check nothing about an enforcement agreement. Neither the decree nor its current status was checked, and no web substitute was used. The Generator's own flag stands and is the important half: the Scores table leans on this decree as the one opening in a crowded field, and whether the sale restrictions are still in force in September 2026 is unknown to this file. A two-year-old enforcement dislocation is the kind of fact most likely to have moved. This needs a human to read the docket or Philips' current investor filings before any competitive-intensity score rests on it — source: no connector covers court dockets or FDA enforcement actions; nothing was queried.
claim 24unconfirmedUSAsk ↗
ResMed markets the AirCurve 10 ST-A with iVAPS, and Philips Respironics markets the BiPAP AVAPS, as home bi-level devices with a back-up rate and volume-assured pressure support; SenTec markets the SenTec Digital Monitoring System with the V-Sign sensor for transcutaneous CO2 monitoring, including described use in the patient's home under clinical supervision
jurisdiction: US — confidence: unconfirmed — note: compound over three devices; two resolve cleanly to cleared records, one does not, and "markets" is in any case a commercial fact that a clearance database cannot establish — a cleared device may never have shipped. SenTec: confirmed, and precisely. 510(k)…
the full check K071672, "SENTEC DIGITAL MONITORING SYSTEM", Sentec AG, 2007-09-12; its Indications for Use read "The SenTec Digital Monitoring System — consisting of the SenTec Digital Monitor (SDM), the V-Sign™ Sensor and Accessories — is indicated for continuous, non-invasive patient monitoring ... in hospitals, hospital-type facilities, intra-hospital transport environments, and — if under clinical supervision — home environments." That is the V-Sign sensor and the home-under-clinical-supervision language, both verbatim, from the cleared indication. A later clearance K151329 (2015-12-17) names the V-Sign Sensor explicitly, and K232516 (2024-05-17) is the current SDMS tCOM+. Philips: confirmed as a cleared device — K102465, BIPAP AVAPS VENTILATORY SUPPORT SYSTEM, product code MNS (see claim 18verified). ResMed: not confirmed under the name claimed. openFDA returns no 510(k) for device_name "AirCurve 10 ST-A", "AirCurve 10 ST" or "iVAPS". The nearest record is K161492, "Juno VPAP ST-A", Resmed Ltd., 2017-01-19, whose Indications for Use do name the mode: "The Juno VPAP ST-A is indicated to provide noninvasive ventilation for patients weighing more than 30lbs (13 kg) with respiratory insufficiency or obstructive sleep apnoea (OSA). The iVAPS mode is indicated for patients weighing more than 66lbs (30 kg). The Juno VPAP ST-A is intended for home and hospital use." Whether "Juno VPAP ST-A" is the same platform marketed in the US as "AirCurve 10 ST-A" is a brand-to-clearance mapping this repo cannot make from a database, so it is left for a human. Note also that no IFU (instructions for use) retrieved here uses the phrase "back-up rate" — the back-up-rate characterisation of any of these devices is unverified — source: 510k "SenTec Digital Monitoring System" --applicant "SenTec" --jurisdiction US → verified, openFDA device/510k k_number=K071672; clearance-summary K071672 --jurisdiction US → verified, FDA 510(k) summary K071672 (https://www.accessdata.fda.gov/cdrh_docs/pdf7/K071672.pdf); 510k "AirCurve 10 ST-A" --applicant "ResMed" --jurisdiction US → refuted: "No 510(k) record found"; 510k "iVAPS" --jurisdiction US → unconfirmed: no record; 510k "VPAP ST-A" --applicant "ResMed" --jurisdiction US → verified, openFDA device/510k k_number=K161492; clearance-summary K161492 --expect-indication "iVAPS" --jurisdiction US → unconfirmed on the phrase, but only because that summary PDF uses a shifted subset-font encoding pypdf cannot map (every character offset by +29); decoded from the connector's own retrieved bytes, the IFU does contain "The iVAPS mode is indicated for patients weighing more than 66lbs (30 kg)". Flagged so a later reader does not read that phrase miss as a finding about the device.
claim 25unconfirmedUSAsk ↗
FTO (freedom to operate)/IP — no patent search was performed. The Generator ran no patent-database query for this candidate and identified no patent number, family or assignee patent list; the FTO field is unexamined, not clear. The two areas the Generator names as the specific risk surfaces, without having searched either, are (a) volume-assured / target-ventilation control algorithms of the kind marketed as iVAPS (ResMed) and AVAPS (Philips Respironics), and (b) transcutaneous CO2 sensor head construction, heating and calibration. A web search for a ResMed iVAPS patent number returned no number
jurisdiction: US — confidence: unconfirmed — note: still unexamined after this pass, and structurally so. patent takes a specific patent number and returns a record for it; there is no patent search connector in this repo, so an assignee-portfolio or subject-matter search — which is what both named risk…
the full check surfaces require — cannot be run here at all, with or without an API key. No invocation was possible: a placeholder like patent <id> is refused by recheck_claims.py rather than guessed at, and inventing a plausible-looking patent number to have something to query would be fabrication. The claim's own statement — that the field is unexamined, not clear — is accurate and is now confirmed as still accurate. Two useful starting points did come out of this pass for whoever runs the search: the ResMed platform is cleared as K161492 "Juno VPAP ST-A" (iVAPS named in the IFU) and the Philips one as K102465, and the sensor surface sits under product code LKD with Sentec AG, Radiometer Medical and Perimed AB as the active assignee candidates (claim 19unconfirmed). Gate-relevant and unchanged: FTO/IP carries the rubric's only automatic kill and nothing has been searched — source: no search-capable patent connector exists in this repo; patent requires a specific patent_id and this file names none, so nothing was queried.
claim 26unconfirmedUSAsk ↗
FTO/IP, second claim — the foundational patents on bi-level positive airway pressure with a back-up rate, filed by the original commercial developers of that modality around 1990, are expected on their ordinary term to have expired, leaving the base modality free to practise
jurisdiction: US — confidence: unconfirmed — note: same structural block as claim 25unconfirmed and for the same reason: no patent number is named, and patent cannot be run without one. Recording what would and would not follow even if it could: the connector returns filing and grant dates with an explicit naive-expiration…
the full check caveat, so a verified result there would be a database fact about dates, never a legal FTO conclusion — term extensions, continuations, and later improvement patents on the same modality are all outside what it sees. So even the most favourable possible outcome on this claim would not clear the base modality; it would only date one document. The inference from the modality's age remains an inference — source: patent requires a specific patent_id; none is named in this file and none was invented, so nothing was queried.
claim 27unconfirmedUSAsk ↗
Assumption, not a fact: the idea depends on pulmonologists and sleep physicians choosing to prescribe a new entrant's respiratory assist device over the incumbent ResMed devices they already use, on the strength of the home tcCO2 channel. There is no connector for prescriber preference and no primary research behind this belief; it is written as an assumption so it stays visible
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research (interviews, a survey, a published preference study), and deliberately not answered from the Verifier's own judgement — a fluent model answer about what prescribers would do is a fabricated stakeholder opinion, not…
the full check evidence. The checkable proxy hiding inside it is incumbent entrenchment, and part of that is now on the record: ResMed and Philips both hold current clearances on the bi-level-with-volume-assurance platforms (K161492, K102465) — source: adoption "pulmonologists and sleep physicians will prescribe a new entrant respiratory assist device over incumbent ResMed devices on the strength of a home tcCO2 channel" → unverifiable: asserts what clinicians, payers or patients would do; needs primary research.
claim 28unconfirmedUSAsk ↗
Assumption, not a fact: the idea depends on the DME supplier channel — Medicare RADs are dispensed and billed by DME suppliers, not sold directly to patients or practices — being willing to stock, set up and service a device carrying an extra consumable sensor, and on that extra service burden fitting inside the E0471 rental allowable. No supplier economics were researched
jurisdiction: US — confidence: unconfirmed — note: re-checked 2026-09-29 from the queue; tag unchanged. The replay's verified on payment E0471 supplies the number this line was waiting for, but it answers neither half of the assumption: the allowable is now known — July 2026 DMEPOS fee schedule, E0471 RR (capped…
the full check rental), non-rural $324.35–$347.40 and rural $520.32–$579.71 per rental month, Medicare allowed amounts with coinsurance inside them, and paid for at most 13 continuous months at a rate that steps down after month 3 (42 CFR 414.229(b)(2), (f)(1); see claim 10unconfirmed) — while supplier willingness and whether the sensor's service burden fits inside that amount remain unresearched. Step one of the two-step item below is done; step two still needs primary supplier research. Previous pass, kept as history: permanently unconfirmed on the preference half; and the one quantitative half that is checkable in principle is blocked on a missing file, which is worth separating. "Does the extra service burden fit inside the E0471 rental allowable" needs the allowable, and the DMEPOS payment cache is absent here (claim 10unconfirmed) — so this assumption cannot even be framed numerically from this repo yet. That makes it a two-step item for whoever picks it up: retrieve the allowable first, then take supplier margin to primary research — source: adoption "DME suppliers will stock, set up and service a respiratory assist device carrying an extra consumable tcCO2 sensor inside the E0471 rental allowable" → unverifiable; payment E0471 --jurisdiction US → unconfirmed: no local cache at data/hcpcs_payment_rates.csv [previous pass]. Today (2026-09-29): payment E0471 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0471, modifier=RR, schedule=DMEPOS, release=July 2026 — answers the allowable only, not the assumption.
claim 29unconfirmedUSAsk ↗
Assumption, not a fact: the idea depends on patients with COPD tolerating and adhering to nightly high-intensity noninvasive ventilation at inspiratory pressures above 20 cm H2O, and on patients or caregivers applying a transcutaneous CO2 sensor correctly at home on the nights it is prescribed. HOT-HMV reports outcomes for a trial population under trial supervision; nothing here establishes adherence in ordinary practice
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research; not answered from Verifier judgement. Three facts from this pass sharpen it rather than settle it. (i) The pressure premise is loosely anchored at best: NCD 240.9 requires IPAP ≥ 15 cm H2O, not > 20 (claim 5refuted), while…
the full check HOT-HMV's median setting was 24 cm H2O (IQR 22-26) (claim 15verified) — so "above 20" is trial practice, not a coverage requirement, and the tolerability question could be reframed at the lower threshold. (ii) NCD 240.9 does impose a hard, auditable adherence bar for continued payment — use "at least 4 hours per 24-hour period, on at least 70% of days in a 30-day period", re-established at 6 months and again at 7-12 months — so adherence here is not only a clinical question but a revenue one. (iii) Nothing anywhere establishes at-home sensor application by patients or caregivers — source: adoption "patients with COPD will tolerate and adhere to nightly high-intensity NIV above 20 cm H2O and apply a transcutaneous CO2 sensor correctly at home" → unverifiable; adherence thresholds quoted from ncd 240.9 --jurisdiction US → verified, CMS Pub. 100-3, chapter 1 part 4, section=240.9.
claim 30unconfirmedUSAsk ↗
Assumption, not a fact: the idea depends on treating practitioners accepting a home overnight tcCO2 recording as an adequate basis for setting and documenting NIV settings in place of an attended in-laboratory titration, and on that substitution being acceptable for the documentation NCD 240.9 and LCD L33800 require. Whether the coverage documents permit or contemplate home-recorded CO2 at all was not checked
jurisdiction: US — confidence: unconfirmed — note: the practitioner-acceptance half is permanently unconfirmed absent primary research. The coverage-document half was checked this pass, and the answer is not comfortable. NCD 240.9 contains the word "transcutaneous" nowhere. Every CO2 measurement it specifies is…
the full check arterial: entry requires "persistent hypercapnia as demonstrated by PaCO2 ≥ 52 mmHg (millimetres of mercury) by arterial blood gas during awake hours while breathing his/her prescribed FiO2", and the 6-month continuing criteria are framed on PaCO2 — "Normalization (< 46 mmHg) of PaCO2, or Stabilization of a rising PaCO2, or 20% reduction in PaCO2 from baseline value", or symptom improvement. The NCD also does not require an attended in-laboratory titration, and explicitly waives formal sleep testing where the clinician judges sleep apnea is not the predominant cause — so what the device would be displacing may not be a covered facility study in the first place, which cuts at the economic argument from the other side. Note carefully what this does and does not show: the NCD is silent on transcutaneous recording, which is not the same as prohibiting it, and the NCD's PaCO2 criteria are eligibility and outcome measures rather than titration documentation. LCD L33800, which is where documentation requirements would actually live, was not read — no connector reaches LCD text (claim 6unconfirmed). The Generator's instinct that this is the assumption most worth converting first is correct and this pass reinforces it — source: ncd 240.9 --expect "transcutaneous" --jurisdiction US → unconfirmed: "exists and was read, but its text does NOT contain the phrase 'transcutaneous'", CMS Pub. 100-3, chapter 1 part 4, section=240.9; adoption "treating practitioners will accept a home overnight tcCO2 recording in place of an attended in-laboratory titration for setting and documenting NIV settings" → unverifiable; coverage E0471 --jurisdiction US → unconfirmed: no local cache, LCD not reachable [previous pass]. Re-run 2026-09-29 with the coverage cache present: coverage E0471 --jurisdiction US → refuted, "no policy names this code" — a blank-codes linkage artefact (A52517, the RAD policy article attached to L33800, is in the cache with an empty codes column; see claim 6unconfirmed), not a finding about coverage, and still no LCD text is reachable. Tag unchanged.
claim 31unconfirmedUSAsk ↗
Medicare beneficiaries prescribed an E0471 respiratory assist device for CRF consequent to COPD will accept the beneficiary cost share on the capped-rental allowable, plus any non-covered charge for the reusable transcutaneous CO2 sensor and its consumables, without abandoning therapy.
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research — what beneficiaries would do is a stakeholder-behaviour claim, and it is not answered from Verifier judgement. The checkable number inside it is now on the record: the E0471 monthly allowable is non-rural…
the full check $324.35–$347.40 and rural $520.32–$579.71 (July 2026 DMEPOS, RR, capped rental), and the connector notes beneficiary coinsurance comes out of that allowed amount; the coinsurance percentage itself and any sensor charge were not looked up, and no HCPCS Level II descriptor names a transcutaneous CO2 sensor (claim 34unconfirmed) — source: adoption "Medicare beneficiaries prescribed an E0471 respiratory assist device will accept the beneficiary cost share and any non-covered tcCO2 sensor charge without abandoning therapy" → unverifiable: "asserts what clinicians, payers, or patients would do"; payment E0471 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0471, modifier=RR, schedule=DMEPOS, release=July 2026. Origin: deck-surfaced assumption (desirability deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 32unconfirmedUSAsk ↗
A US clinical practice guideline or specialty-society recommendation endorses long-term home noninvasive ventilation for chronic hypercapnic COPD, and prescribing pulmonologists and sleep physicians cite it when deciding whether to initiate home NIV.
jurisdiction: US — confidence: unconfirmed — note: compound; the first half has a strong pointer and the second half is permanently unconfirmed. (1) A US specialty-society guideline exists: PubMed returns "Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An…
the full check Official American Thoracic Society Clinical Practice Guideline" (Am J Respir Crit Care Med, 2020, PMID 32795139), whose abstract reads "We suggest the use of nocturnal NIV in addition to usual care for patients with chronic stable hypercapnic COPD (conditional recommendation, moderate certainty)". That is a conditional suggestion, not a strong endorsement, and it is read off a literature ScanResult (title and structured abstract), which carries no tag of its own — so it is recorded as a pointer, not as a verification. Two further recommendations in the same abstract bear on this device: "we suggest not using an in-laboratory overnight polysomnogram to titrate NIV" (cuts at the facility-displacement argument, claim 14b) and "we suggest NIV with targeted normalization of PaCO2" (a PaCO2 target, not a tcCO2 one; see claim 37unconfirmed). (2) That prescribers cite it when deciding is a clinician-behaviour claim with no connector and no primary research — adoption is unverifiable by design — source: literature "American Thoracic Society clinical practice guideline long-term noninvasive ventilation chronic stable hypercapnic COPD" --since 2015-01-01 --limit 10 → found, 2 records incl. PubMed PMID=32795139 and PMID=33326340 (summary for clinicians); literature-detail 32795139 → found, PubMed PMID=32795139 (efetch), https://pubmed.ncbi.nlm.nih.gov/32795139/; adoption "prescribing pulmonologists and sleep physicians cite a US guideline when deciding whether to initiate home NIV for hypercapnic COPD" → unverifiable. Origin: deck-surfaced assumption (desirability deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 33unconfirmedUSAsk ↗
Adults with COPD, or their caregivers, can apply a reusable transcutaneous CO2 sensor at the ear or chest at home unaided and produce an overnight recording the treating practitioner judges interpretable.
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research (a usability or home-use study); not answered from Verifier judgement. Context only: the one cleared tcCO2 system with home language, SenTec K071672, is indicated for home environments "if under clinical supervision"…
the full check (claim 24unconfirmed) — which is the opposite of unaided, and says nothing about whether unaided application works — source: adoption "adults with COPD or caregivers can apply a reusable transcutaneous CO2 sensor at home unaided and produce an interpretable overnight recording" → unverifiable: "asserts what clinicians, payers, or patients would do". Origin: deck-surfaced assumption (desirability deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 34unconfirmedUSAsk ↗
A Medicare-payable HCPCS code, or an established payment mechanism inside the E0471 capped-rental allowable, covers the reusable transcutaneous CO2 sensor and its consumables so that the recording channel is not delivered unpaid.
jurisdiction: US — confidence: unconfirmed — note: neither route is shown. (1) No dedicated code found: the cached CMS HCPCS Level II file (October 2026) was searched for "transcutaneous", "carbon dioxide" and "CO2"; every "transcutaneous" descriptor is a nerve/joint stimulator (E0720–E0770, A4540 (a HCPCS code for a supply), A4543, K1016,…
the full check K1023) and the only "carbon dioxide" descriptor is a blood product (P9027) — no Level II code describes a transcutaneous CO2 sensor or its consumables. That is a search of one file by descriptor wording, not proof that no code could be used (a miscellaneous or NOC code, or a future code, is outside it), so it is not recorded as refuted. (2) Whether the sensor is bundled inside the E0471 capped-rental allowable is a payment-policy question the fee schedule does not answer — it prices E0471 (RR only, capped rental) and says nothing about what the rental must include; no connector reads the DME MAC policy article (A52517) text. A human should read A52517 and the DME MAC's bundling rules — source: hcpcs E0471 --jurisdiction US → verified, local cache of CMS HCPCS Level II file, code=E0471 (existence of the base code only); payment E0471 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0471, modifier=RR, schedule=DMEPOS, release=July 2026; descriptor search of data/hcpcs_level_ii.csv (CMS October 2026 alpha-numeric HCPCS file) for transcutaneous / carbon dioxide / CO2 — no sensor code. Origin: deck-surfaced assumption (viability deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 35unconfirmedUSAsk ↗
A patentable claim is available over the integration of overnight transcutaneous CO2 recording with practitioner-approved bi-level titration recommendations that is not anticipated by ResMed's, Philips Respironics' or SenTec's existing filings.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed, and structurally so — patentability over prior art is a legal judgement (Tier 3), and no connector returns it. Leads only, no tag: patent-scan with the claim's own vocabulary matched nothing (which is not a clear field), and a CPC-scoped sweep of A61M16…
the full check with "transcutaneous" in title/abstract returned 12 families, none on its title an integration of tcCO2 recording with bi-level titration recommendations; the closest title is EP3238768A1 "System for delivering oxygen and preventing hypercapnia" (2017). ResMed-, Philips- and SenTec-assignee sweeps were not run this pass; the claim names those three portfolios specifically, so this is the next search, followed by patent <id> on any close family — source: patent-scan --text "transcutaneous carbon dioxide ventilation titration" --limit 25 --jurisdiction US → none, 0 publications ("Not a clear field"); patent-scan --cpc A61M16 --text transcutaneous --limit 25 --jurisdiction US → found, 12 families (ScanResult, leads only). Origin: deck-surfaced assumption (viability deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 36unconfirmedUSAsk ↗
Patients enrolled on an E0471 rental under NCD 240.9 sustain the NCD's continued-coverage adherence bar at re-establishment at 6 months and again at 7-12 months, at a rate high enough that monthly rental revenue continues through the capped-rental period.
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research or a published persistence study; not answered from Verifier judgement. Two facts frame it without settling it: NCD 240.9's continued-coverage bar is use "at least 4 hours per 24-hour period, on at least 70% of days in a…
the full check 30-day period" (claim 29unconfirmed), and 42 CFR 414.229(f)(1) pays capped rental "for no longer than a period of continuous use of 13 months" (claim 10unconfirmed). The DMEPOS utilization file shows 188,380 E0471 rental services across 32,920 beneficiaries in the data year (≈5.7 rental months per beneficiary) — but that is a one-year snapshot that mixes patients starting, finishing and completing their 13 months, so it is not a persistence or adherence rate and must not be read as one — source: adoption "patients on an E0471 rental under NCD 240.9 sustain the continued-coverage adherence bar through the capped-rental period" → unverifiable; procedures E0471 --jurisdiction US → verified, local cache of CMS Medicare DMEPOS utilization file, code=E0471, geography=National — "rental 188,380 services / 32,920 beneficiaries" (context, not an answer). Origin: deck-surfaced assumption (viability deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 37unconfirmedUSAsk ↗
Overnight transcutaneous CO2 recorded at home with a reusable ear or chest sensor agrees with arterial PaCO2 closely enough, and drifts little enough across the night, to serve as the titration target for high-intensity noninvasive ventilation rather than only as an adjunct indicator of relative change.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed — a clinical-performance claim with no connector that answers it, and the one primary regulatory text in reach frames the device type more narrowly than the claim needs. 21 CFR 868.2480 identifies a cutaneous CO2 monitor as intended "to monitor relative…
the full check changes in a hemodynamically stable patient's cutaneous carbon dioxide tension as an adjunct to arterial carbon dioxide tension measurement" — the claim itself anticipates this ("rather than only as an adjunct indicator of relative change"), and the regulation describes precisely the narrower use. The regulation says nothing about accuracy, agreement or drift; those need method-comparison studies, which were not searched or appraised. Also relevant: the ATS 2020 guideline's recommendation is for "targeted normalization of PaCO2" (claim 32unconfirmed), an arterial target — source: regulation 868.2480 --title 21 --expect "adjunct to arterial carbon dioxide tension measurement" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-25, section=868.2480 (the phrase is present; it frames the device and does not answer the claim). Origin: deck-surfaced assumption (feasibility deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 38unconfirmedUSAsk ↗
FDA accepts a 510(k) for a combined home bi-level ventilator with an integrated overnight transcutaneous CO2 recording channel and practitioner-approved titration recommendations, without requiring a De Novo (De Novo classification request) request or a clinical study.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed — a prediction about an FDA decision not yet made; no database can verify it, and a pre-submission is the only instrument that could inform it. Checked against this file's intended_use: (prescription home bi-level NIV with back-up rate for adults with…
the full check CRF consequent to COPD, recording overnight tcCO2 for practitioner review, no automatic setting changes) — a move to closed-loop control would change the question. What the record does show: the two functions are cleared under disjoint product codes (MNS, 21 CFR 868.5895; LKD, 21 CFR 868.2480 — claims 18, 19), with no combined-function predicate found; and the cached FDA De Novo listing (494 grants) holds no grant matching "ventilator" or "carbon dioxide", so there is no De Novo precedent for this device type either way. That denovo miss refutes only the existence of a matching De Novo grant, not the claim, and is not carried as a tag — source: denovo "ventilator" --jurisdiction US → refuted: "No granted De Novo request matching 'ventilator' in the cached FDA De Novo listing (494 records)" (about the listing only); denovo "carbon dioxide" --jurisdiction US → refuted: no match, same listing (about the listing only). Origin: deck-surfaced assumption (feasibility deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 39unconfirmedUSAsk ↗
A reusable transcutaneous CO2 sensor holds calibration across an unattended overnight home recording without mid-session recalibration or membrane change, at a skin-heating temperature that causes no thermal injury to elderly COPD patients.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed — a bench/clinical performance and safety claim about a sensor that does not yet exist in this form; no connector covers device performance testing or thermal-injury data, and nothing was queried. The places a human would look are the LKD predicate 510(k)…
the full check summaries already identified (SenTec K071672, K151329, K232516; claims 19, 24) for stated monitoring duration, calibration interval and sensor temperature, and MAUDE (Manufacturer and User Facility Device Experience) for burn reports under product code LKD — neither was run this pass — source: no connector covers sensor calibration stability or thermal safety; nothing was queried. Origin: deck-surfaced assumption (feasibility deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 40unconfirmedUSAsk ↗
The titration-recommendation software rejects overnight traces corrupted by sensor detachment, poor skin contact or artefact rather than computing a settings proposal from them, and presents the rejection to the treating practitioner.
jurisdiction: US — confidence: unconfirmed — note: unconfirmed — this is a design requirement for the candidate's own, unbuilt software, not a fact about the world; no primary source can verify it and no connector applies. It belongs in a design-input / verification plan, where it is testable — source: no connector…
the full check applies to an unbuilt device's software behaviour; nothing was queried. Origin: deck-surfaced assumption (feasibility deck, 2026-09-20) (Verifier pass 2026-09-29).
claim 41unverifiedUSAsk ↗
US pulmonologists and sleep physicians who initiate home noninvasive ventilation for chronic hypercapnic COPD would change ventilation settings on the basis of a home overnight transcutaneous CO2 recording in cases where, without that recording, they would leave the settings unchanged or adjust them only on a daytime arterial blood gas.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future)
claim 42unverifiedUSAsk ↗
Adults with chronic respiratory failure consequent to COPD who are offered home noninvasive ventilation with overnight transcutaneous CO2 recording decline or discontinue therapy no more often than comparable patients offered home bi-level ventilation without the sensor.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future)
claim 43unverifiedUSAsk ↗
DME suppliers will pay a higher unit price for an E0471 respiratory assist device with an integrated transcutaneous CO2 recording channel than for a standard E0471 device, even though Medicare pays both at the same E0471 capped-rental allowable.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-09-29) — never checked; recorded so the Verifier can see it — evidence class 3 (stakeholder future)
claim 44unverifiedUSAsk ↗
The share of Medicare fee-for-service E0471 rental beneficiaries whose device is supplied for chronic respiratory failure consequent to COPD under NCD 240.9, as distinct from other respiratory-assist-device indications, is reported in or derivable from a CMS primary data source.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-09-29) — never checked; recorded so the Verifier can see it
claim 45unverifiedUSAsk ↗
The combined bi-level ventilator and transcutaneous CO2 recording system can be cleaned and reprocessed between successive rental patients by a DME supplier, and its consumable sensor element replaced by the supplier's staff in the patient's home, without manufacturer field service.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-29) — never checked; recorded so the Verifier can see it
Words on this page34 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md
21 CFR
Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k)
premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
A####
a HCPCS code for a supply — one billing code for a supply or an accessory; the letter A and four digits
Class II
FDA device class II — moderate-risk devices, usually cleared by 510(k)
Class III
FDA device class III — the highest-risk devices, usually approved by PMA
CMS
Centers for Medicare & Medicaid Services — the US agency that runs Medicare, and so decides what Medicare pays for
CPT
Current Procedural Terminology — the US billing codes for what a clinician does; owned by the American Medical Association
De Novo
De Novo classification request — the FDA route for a new, lower-risk device with no comparable product to point at; longer than a 510(k), usually needs clinical data
DME
durable medical equipment — equipment a patient uses at home, such as a pump or a stimulator, that Medicare pays for under its own rules
DME MAC
durable medical equipment Medicare administrative contractor — one of the four regional contractors that process Medicare's home-equipment claims and write its local coverage rules
DMEPOS
durable medical equipment, prosthetics, orthotics and supplies — the Medicare benefit and fee schedule that home equipment is paid under
E####
a HCPCS code for durable medical equipment — one billing code for a piece of home equipment; the letter E and four digits
FDA
US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
FFS
fee-for-service — the traditional form of Medicare that pays per item or service
FTO
freedom to operate — whether a product can be sold without infringing someone else's live patent
HCPCS
Healthcare Common Procedure Coding System — the US billing codes for equipment, supplies and some services; a code is how a payer recognises what to pay for
IFU
instructions for use — the labelling that says what a device is for and how to use it
K######
an FDA 510(k) clearance number — the public record of one cleared device; the letter K and six digits
L#####
a Medicare local coverage determination number — the public id of one local coverage rule; the letter L and five digits
LCD
local coverage determination — a Medicare contractor's rule, valid in its region, saying when something is covered
MAC
Medicare administrative contractor — a regional contractor that processes Medicare claims and writes local coverage rules
MAUDE
Manufacturer and User Facility Device Experience — the FDA's public database of reported device problems
Medicare Advantage
Medicare Advantage — Medicare delivered through a private insurer; must cover at least what Medicare covers
mmHg
millimetres of mercury — the unit blood pressure, and the suction of a wound pump, are measured in
NCD
national coverage determination — a Medicare rule, valid everywhere in the US, saying whether and when something is covered
NCD ###.#
a Medicare national coverage determination number — the public id of one national coverage rule
NCT########
a ClinicalTrials.gov registration number — the public id of one registered clinical trial
NIV
non-invasive ventilation — breathing support through a mask rather than a tube
OSA
obstructive sleep apnoea — breathing that repeatedly stops during sleep because the airway closes
PFS
physician fee schedule — the Medicare price list for what clinicians do
PMID
PubMed identifier — the public id of one published medical paper
RVU
relative value unit — the unit Medicare uses to price a clinician's work
TAM
total addressable market — how much money the whole market would be worth if every possible buyer bought
tcCO2
transcutaneous carbon dioxide — carbon dioxide measured through the skin, as a stand-in for a blood test